Ishii Midori, Suehara Yoshiyuki, Sano Kei, Kohsaka Shinji, Hayashi Takuo, Kazuno Saiko, Akaike Keisuke, Mukaihara Kenta, Kim Youngji, Okubo Taketo, Takamochi Kazuya, Takahashi Fumiyuki, Kaneko Kazuo, Saito Tsuyoshi
Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Oncotarget. 2018 Dec 25;9(101):37509-37519. doi: 10.18632/oncotarget.26493.
Synovial sarcoma (SS) is a malignant soft tissue lesion and most commonly arises in young adults. Chromosomal translocation t(X;18)(p11;q11) results in the formation of / by gene fusion of the SS18 gene on chromosome 18 to either , , or gene located on chromosome X, which is detected in more than 95% of SSs. Although multiple lines of evidence suggest that the fusion is the oncogene in this tumor, the protein expression profiles associated with / have yet to be elucidated. In this study, we conducted proteomic studies using / knockdown in three SS cell lines to identify the regulated proteins associated with SS18/SSX in SS. Isobaric tags for relative and absolute quantitation (i-TRAQ) analyses identified approximate 1700-2,000 proteins regulated by the SS18/SSX fusion in each SS cell line. We also analyzed the three profiles to identify proteins that were similarly altered in all 3 cell lines and found 17 consistently upregulated and 18 consistently downregulated proteins, including TAGLN and ACTN4. In addition, network analyses identified several critical pathways including RUNX2 and SMARCA4. RUNX2 and SMARCA4 had the highest ranking in these identified pathways. In addition, we found that expression of TAGLN inhibited cell viability in SS cell lines. Our data suggest that the differentiation and cell growth of SS may be enhanced by the identified proteins induced by SS18/SSX. We believe that the findings obtained in the present functional analyses will help to improve our understanding of the relationship between SS18/SSX and malignant behavior in SS.
滑膜肉瘤(SS)是一种恶性软组织病变,最常见于年轻人。染色体易位t(X;18)(p11;q11)导致18号染色体上的SS18基因与X染色体上的 、 或 基因发生基因融合,从而形成 ,在超过95%的滑膜肉瘤中可检测到这种融合。尽管多方面证据表明 融合是该肿瘤中的致癌基因,但与 相关的蛋白质表达谱尚未阐明。在本研究中,我们在三种滑膜肉瘤细胞系中使用 敲低进行蛋白质组学研究,以鉴定滑膜肉瘤中与SS18/SSX相关的受调控蛋白质。相对和绝对定量同位素标记(i-TRAQ)分析在每个滑膜肉瘤细胞系中鉴定出约1700 - 2000种受SS18/SSX融合调控的蛋白质。我们还分析了这三种蛋白质谱,以鉴定在所有三种细胞系中均有类似变化的蛋白质,发现了17种持续上调和18种持续下调的蛋白质,包括TAGLN和ACTN4。此外,网络分析确定了包括RUNX2和SMARCA4在内的几个关键通路。RUNX2和SMARCA4在这些确定的通路中排名最高。此外,我们发现TAGLN的表达抑制滑膜肉瘤细胞系中的细胞活力。我们的数据表明,滑膜肉瘤的分化和细胞生长可能由SS18/SSX诱导的已鉴定蛋白质增强。我们相信,在目前的功能分析中获得的结果将有助于增进我们对SS18/SSX与滑膜肉瘤恶性行为之间关系的理解。